WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension

被引：41

作者：

Savale, Laurent ^{[1
,2
,3
]}

Huitema, Marloes ^{[4
,5
]}

Shlobin, Oksana ^{[6
]}

Kouranos, Vasilis ^{[7
,8
]}

Nathan, Steven D. ^{[6
]}

Nunes, Hiliaro ^{[9
,10
]}

Gupta, Rohit ^{[11
]}

Grutters, Jan C. ^{[5
,12
]}

Culver, Daniel A. ^{[13
]}

Post, Marco C. ^{[4
,5
]}

Ouellette, Daniel ^{[14
]}

Lower, Elyse E. ^{[15
]}

Al-Hakim, Tamara ^{[16
]}

Wells, Athol U. ^{[7
,8
]}

Humbert, Marc ^{[1
,2
,3
]}

Baughman, Robert P. ^{[15
]}

机构：

[1] Univ Paris Saclay, Le Kremlin Bicetre, France

[2] INSERM UMR S 999, Le Kremlin Bicetre, France

[3] Hop Bicetre, AP HP, Serv Pneumol & Soins Intensifs Resp, Le Kremlin Bicetre, France

[4] St Antonius Hosp, Dept Cardiol, Nieuwegein, Netherlands

[5] Univ Med Ctr Utrecht, Utrecht, Netherlands

[6] Inova Fairfax Hosp, Adv Lung Dis & Transplant Program, Falls Church, VA USA

[7] Royal Brompton Hosp, Interstitial Lung Dis Sarcoidosis Unit, London, England

[8] Imperial Coll, Natl Heart & Lung Inst, London, England

[9] Univ Sorbonne Paris Nord, INSERM UMR 1272, Bobigny, France

[10] Hop Avicenne, AP HP, Ctr Reference Malad Pulmonaires Rares, Serv Pneumol, Bobigny, France

[11] Temple Univ, Lewis Katz Sch Med, Dept Thorac Med & Surg, Philadelphia, PA 19122 USA

[12] St Antonius Hosp, ILD Ctr Excellence, Dept Pulmonol, Nieuwegein, Netherlands

[13] Cleveland Clin, Cleveland, OH 44106 USA

[14] Henry Ford Hosp, Detroit, MI 48202 USA

[15] Univ Cincinnati, Med Ctr, Dept Med, Cincinnati, OH 45267 USA

[16] Fdn Sarcoidosis Res, Chicago, IL USA

来源：

EUROPEAN RESPIRATORY REVIEW | 2022年 / 31卷 / 163期

关键词：

OBSTRUCTIVE SLEEP-APNEA; ARTERIAL-HYPERTENSION; SINGLE-CENTER; CLINICAL CHARACTERISTICS; EPOPROSTENOL THERAPY; CARDIAC SARCOIDOSIS; OUTCOMES; ABNORMALITIES; HEMODYNAMICS; AMBRISENTAN;

D O I：

10.1183/16000617.0165-2021

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Sarcoidosis-associated pulmonary hypertension (SAPH) is an important complication of advanced sarcoidosis. Over the past few years, there have been several studies dealing with screening, diagnosis and treatment of SAPH. This includes the results of two large SAPH-specific registries. A task force was established by the World Association of Sarcoidosis and Other Granulomatous disease (WASOG) to summarise the current level of knowledge in the area and provide guidance for the management of patients. A group of sarcoidosis and pulmonary hypertension experts participated in this task force. The committee developed a consensus regarding initial screening including who should undergo more specific testing with echocardiogram. Based on the results, the committee agreed upon who should undergo right-heart catheterisation and how to interpret the results. The committee felt there was no specific phenotype of a SAPH patient in whom pulmonary hypertension-specific therapy could he definitively recommended. They recommended that treatment decisions be made jointly with a sarcoidosis and pulmonary hypertension expert. The committee recognised that there were significant defects in the current knowledge regarding SAPII, but felt the statement would be useful in directing future studies.

引用

页数：17

共 82 条

[1] LONG-TERM OUTCOMES OF EPOPROSTENOL THERAPY IN SARCOID ASSOCIATED PULMONARY HYPERTENSION [J].